Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$11.06 -4.2%	$10.30	$3.85 ▼ $12.43	$1.75B	1.83	1.63 million shs	1.59 million shs
BEAM Beam Therapeutics	$19.58 -7.5%	$17.83	$13.53 ▼ $35.25	$2.13B	2.07	1.56 million shs	3.01 million shs
GH Guardant Health	$48.09 -3.4%	$45.94	$20.14 ▼ $53.42	$6.17B	1.44	2.16 million shs	1.84 million shs
VCYT Veracyte	$25.24 -5.3%	$27.52	$19.73 ▼ $47.32	$2.09B	2.07	917,327 shs	696,508 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-4.24%	-5.79%	+7.17%	+47.66%	+174.44%
BEAM Beam Therapeutics	-7.51%	-3.55%	+14.77%	+17.81%	-23.58%
GH Guardant Health	-3.38%	-5.37%	-2.43%	+6.44%	+52.47%
VCYT Veracyte	-5.29%	-5.04%	-4.54%	-19.95%	+11.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.8494 of 5 stars	1.4	1.0	4.2	3.1	2.5	0.6
BEAM Beam Therapeutics	2.2731 of 5 stars	3.5	0.0	0.0	3.2	2.5	0.6
GH Guardant Health	4.4791 of 5 stars	3.5	3.0	4.4	3.3	2.5	0.6
VCYT Veracyte	3.562 of 5 stars	3.4	1.0	4.3	2.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	-4.42% Downside
BEAM Beam Therapeutics	3.00	Buy	$48.75	148.98% Upside
GH Guardant Health	3.05	Buy	$53.76	11.79% Upside
VCYT Veracyte	2.70	Moderate Buy	$40.90	62.04% Upside

Current Analyst Ratings Breakdown

Latest VCYT, ADPT, BEAM, and GH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	GH Guardant Health	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/13/2025	GH Guardant Health	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $65.00
5/8/2025	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $42.00
5/8/2025	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $41.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/6/2025	GH Guardant Health	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $60.00
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$189.53M	8.87	N/A	N/A	$1.37 per share	8.07
BEAM Beam Therapeutics	$63.52M	31.00	N/A	N/A	$8.86 per share	2.21
GH Guardant Health	$739.02M	8.06	N/A	N/A	($1.13) per share	-42.56
VCYT Veracyte	$463.39M	4.27	$0.98 per share	25.70	$15.17 per share	1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
GH Guardant Health	-$436.37M	-$3.39	N/A	N/A	N/A	-53.82%	N/A	-26.77%	7/30/2025 (Estimated)
VCYT Veracyte	$24.14M	$0.41	61.56	35.06	N/A	7.13%	6.14%	5.60%	8/5/2025 (Estimated)

Latest VCYT, ADPT, BEAM, and GH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	GH Guardant Health	-$0.52	N/A	N/A	N/A	$211.19 million	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
8/5/2025	Q2 2025	VCYT Veracyte	$0.31	N/A	N/A	N/A	$120.90 million	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million
4/30/2025	Q1 2025	GH Guardant Health	-$0.57	-$0.49	+$0.08	-$0.77	$189.91 million	$203.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
BEAM Beam Therapeutics	N/A	8.81	8.81
GH Guardant Health	N/A	4.11	3.76
VCYT Veracyte	N/A	5.10	4.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
BEAM Beam Therapeutics	99.68%
GH Guardant Health	92.60%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
BEAM Beam Therapeutics	3.50%
GH Guardant Health	6.10%
VCYT Veracyte	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
GH Guardant Health	2,021	123.89 million	116.33 million	Not Optionable
VCYT Veracyte	790	78.32 million	77.22 million	Optionable

VCYT, ADPT, BEAM, and GH Headlines

Recent News About These Companies

New York State Common Retirement Fund Sells 118,642 Shares of Veracyte, Inc. (NASDAQ:VCYT)

3 hours ago | marketbeat.com

Rice Hall James & Associates LLC Acquires 19,843 Shares of Veracyte, Inc. (NASDAQ:VCYT)

July 15 at 5:45 AM | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Teacher Retirement System of Texas

July 14 at 3:46 AM | marketbeat.com

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 - Morningstar

July 10, 2025 | morningstar.comM

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

July 9, 2025 | tmcnet.com

Wealth Enhancement Advisory Services LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT)

July 6, 2025 | marketbeat.com

Veracyte, Inc. (VCYT) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Sumitomo Mitsui Trust Group Inc.

July 1, 2025 | marketbeat.com

Wall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to Hold

June 28, 2025 | marketbeat.com

AMI Asset Management Corp Has $1.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)

June 26, 2025 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Analysts

June 23, 2025 | marketbeat.com

Veracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last year

June 20, 2025 | finance.yahoo.com

GAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT)

June 19, 2025 | marketbeat.com

Cathie Wood’s ARK buys BWX stock, sells Adaptive Biotech

June 18, 2025 | investing.com

Exchange Traded Concepts LLC Increases Stake in Veracyte, Inc. (NASDAQ:VCYT)

June 17, 2025 | marketbeat.com

Veracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved Profitability

June 9, 2025 | msn.com

Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems

June 7, 2025 | benzinga.com

Insider Selling: John Leite Sells Shares of Veracyte Inc (VCYT)

June 6, 2025 | gurufocus.com

Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?

June 6, 2025 | msn.com

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant

June 4, 2025 | investing.com

Veracyte (VCYT) Shares Pulled Back Despite Beating Expectations

June 3, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, ADPT, BEAM, and GH Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$11.06 -0.49 (-4.24%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$11.02 -0.04 (-0.33%)

As of 07:00 AM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Beam Therapeutics NASDAQ:BEAM

$19.58 -1.59 (-7.51%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$19.82 +0.24 (+1.20%)

As of 07:12 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Guardant Health NASDAQ:GH

$48.09 -1.68 (-3.38%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$47.98 -0.12 (-0.24%)

As of 07:06 AM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Veracyte NASDAQ:VCYT

$25.24 -1.41 (-5.29%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$25.34 +0.10 (+0.38%)

As of 07:12 AM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time